ライフサイエンスコーパス: hypercholesterolemia

1 ] for hypertension, and 2.57 [2.40-2.75] for hypercholesterolemia).

2 n of the APOB gene as treatment for familial hypercholesterolemia.

3 the subgroup of concurrent hypertension and hypercholesterolemia.

4 f the drug ezetimibe, which is used to treat hypercholesterolemia.

5 ic plaques in humans and in a mouse model of hypercholesterolemia.

6 ving lopinavir/ritonavir-based regimens with hypercholesterolemia.

7 atherosclerosis, but only in the setting of hypercholesterolemia.

8 available for patients with the most extreme hypercholesterolemia.

9 roved as a treatment for homozygous familial hypercholesterolemia.

10 erapeutic strategy in stroke associated with hypercholesterolemia.

11 thophysiology of autosomal-dominant familial hypercholesterolemia.

12 0(-17)), but did not have classical familial hypercholesterolemia.

13 tions have a rare form of autosomal dominant hypercholesterolemia.

14 tected in a national universal screening for hypercholesterolemia.

15 mibe and was well tolerated in patients with hypercholesterolemia.

16 To investigate hepatic T-cell subsets upon hypercholesterolemia.

17 reducing the risk of coronary disorders and hypercholesterolemia.

18 ernative for statin-intolerant patients with hypercholesterolemia.

19 nistic target for the control of obesity and hypercholesterolemia.

20 ons are issued per year for statins to treat hypercholesterolemia.

21 ched diet, demonstrating a lack of effect of hypercholesterolemia.

22 tasis and deficiency in LDLR functions cause hypercholesterolemia.

23 patic HIF-2alpha (but not HIF-1alpha) led to hypercholesterolemia.

24 by body weight and comorbid hypertension and hypercholesterolemia.

25 in the vascular dysfunction associated with hypercholesterolemia.

26 a novel pharmacological target for treating hypercholesterolemia.

27 iabetes mellitus (DM), hypertension (HT) and hypercholesterolemia.

28 ith clinically diagnosed homozygous familial hypercholesterolemia.

29 hypertension, smoking, body mass index, and hypercholesterolemia.

30 l absorption by the intestine contributes to hypercholesterolemia.

31 lerosis development in a context of moderate hypercholesterolemia.

32 t study in patients with homozygous familial hypercholesterolemia.

33 ts of sirolimus are hypertriglyceridemia and hypercholesterolemia.

34 eatment of patients with homozygous familial hypercholesterolemia.

35 ow improved management of conditions such as hypercholesterolemia.

36 s an FDA approved drug for treating familial hypercholesterolemia.

37 vascular disease, hypertension, diabetes, or hypercholesterolemia.

38 g hepatocyte production of apoB and treating hypercholesterolemia.

39 tanding of diseases like atherosclerosis and hypercholesterolemia.

40 ven though they exhibited different types of hypercholesterolemia.

41 mutations affect LDL metabolism and lead to hypercholesterolemia.

42 patients with nephrotic syndrome-associated hypercholesterolemia.

43 orbidities or who have heterozygous familial hypercholesterolemia.

44 s had a score highly suggestive of polygenic hypercholesterolemia.

45 had positive screening results for familial hypercholesterolemia.

46 reased platelet activation in the setting of hypercholesterolemia.

47 litus, 17 420 of hypertension, and 24 385 of hypercholesterolemia.

48 had positive screening results for familial hypercholesterolemia (0.3% of the 10,095 children; 95% c

49 had positive screening results for familial hypercholesterolemia (0.4% of the 10,095 children, inclu

50 The most common long-term events were hypercholesterolemia (31%) and osteoporosis (19%).

51 r of patients, however, suffer from familial hypercholesterolemia 4 (FH4), defined as ADH in absence

52 espectively; OR = 3.8; 95% CI, 1.0-14.6) and hypercholesterolemia (50.0% vs 32.7%, respectively; OR =

53 of p.G116S had a 3.02-fold increased risk of hypercholesterolemia (95% confidence interval, 2.34-3.90

54 % confidence interval: 1-3; P=0.05), 2.9 for hypercholesterolemia (95% confidence interval: 1-5; P=0.

55 Hypercholesterolemia, a common comorbidity of obesity, h

56 wine model of ischemia-reperfusion (IR) that hypercholesterolemia abolishes HDL-related cardioprotect

57 Hypercholesterolemia acts in platelets and hematopoietic

58 Hypercholesterolemia acts synergistically with LNK defic

59 Autosomal-dominant hypercholesterolemia (ADH) is characterized by elevated

60 hanges in the lipid profile of children with hypercholesterolemia, although a potential benefit of lo

61 et production and activity in the setting of hypercholesterolemia, amenable to pharmaceutical interve

62 cluding diabetes mellitus, hypertension, and hypercholesterolemia among 69 505 US women in the Nurses

63 The most common cause is autosomal dominant hypercholesterolemia, an inherited disorder caused by mu

64 , Pod-ATTAC mice and NTS-treated mice showed hypercholesterolemia and a 7- to 24-fold induction in pl

65 n of dominant-active IDOL is associated with hypercholesterolemia and a marked elevation in atheroscl

66 Statins are a class of drugs used to treat hypercholesterolemia and are frequently used in the elde

67 PCSK9 as a new modality in the treatment of hypercholesterolemia and associated pathologies.

68 hermore, miR-30c mimic significantly reduced hypercholesterolemia and atherosclerosis in Apoe(-/-) mi

69 ntrast, BAFF overexpression markedly reduced hypercholesterolemia and atherosclerosis in hyperlipidem

70 ghts into identifying therapeutic targets of hypercholesterolemia and atherosclerosis with rabbit mod

71 animal for studying human diseases, such as hypercholesterolemia and atherosclerosis.

72 nd control of inflammation in the context of hypercholesterolemia and atherosclerosis.

73 on of Ldlr with AAV-CRISPR results in severe hypercholesterolemia and atherosclerosis.

74 (Ldlr), which when deleted, leads to severe hypercholesterolemia and atherosclerosis.

75 ls is a viable treatment option for reducing hypercholesterolemia and atherosclerosis.

76 drugs for old patients with hyperlipidemia, hypercholesterolemia and atherosclerotic diseases by red

77 These animals have retinal hypercholesterolemia and convert excess retinal choleste

78 Her medical history was positive for hypercholesterolemia and depression.

79 riate models that adjusted for hypertension, hypercholesterolemia and diabetes (OR 1.31, 95% CI 0.98-

80 nmurine species was demonstrated by inducing hypercholesterolemia and early atherosclerosis in Golden

81 in use for confirmatory testing of familial hypercholesterolemia and for cascade screening of relati

82 CH may provide a target for the treatment of hypercholesterolemia and hyperlipidemia.

83 Individuals with hypercholesterolemia and hypertension who fail to take t

84 Both groups had similar proportions of hypercholesterolemia and hypertriglyceridemia.

85 harmaceutical industry for the management of hypercholesterolemia and its associated cardiovascular d

86 nd December of 2013 in patients with primary hypercholesterolemia and mixed dyslipidemia at 198 sites

87 trial conducted among patients with primary hypercholesterolemia and mixed dyslipidemia, evolocumab

88 FDA for the treatment of homozygous familial hypercholesterolemia and over 35 second generation PS AS

89 arise in the circulation during the onset of hypercholesterolemia and recruit to nascent plaque, but

90 e impact of traditional risk factors such as hypercholesterolemia and smoking.

91 as drugs (e.g., to treat homozygous familial hypercholesterolemia and spinal muscular atrophy) or as

92 -approved statins, which are used to control hypercholesterolemia and target the mevalonate pathway (

93 ed with enhanced macrophage inflammation and hypercholesterolemia and that macrophage alpha1AMPK may

94 insights into the retinal response to local hypercholesterolemia and the retinal significance of cho

95 of a 3-year-old boy with homozygous familial hypercholesterolemia and unstable coronary artery diseas

96 ving positive screening results for familial hypercholesterolemia and were consequently at high risk

97 were 20.1% (with hypertension) and 17% (with hypercholesterolemia) and 24.5% in the group without dia

98 LDL receptor defects (heterozygous familial hypercholesterolemia) and non-familial hypercholesterole

99 ypertension, obesity, abdominal obesity, and hypercholesterolemia), and access to health care (health

100 ma, hyperlipidemia (hypertriglyceridemia and hypercholesterolemia), and lipiduria.

101 cused on screening for heterozygous familial hypercholesterolemia, and 1 review focused on screening

102 trolled for biennially updated hypertension, hypercholesterolemia, and body mass index.

103 led PFOA exposure and incident hypertension, hypercholesterolemia, and coronary artery disease among

104 e mediated by body mass index, hypertension, hypercholesterolemia, and diabetes mellitus.

105 rsening prevalence of obesity, hypertension, hypercholesterolemia, and dysglycemia as the current US

106 n the vessel wall, accumulate in response to hypercholesterolemia, and generate potent pro-inflammato

107 comorbidities, including hepatic steatosis, hypercholesterolemia, and glucose intolerance.

108 tors, including hypertension, hyperglycemia, hypercholesterolemia, and high circulating levels of tri

109 iron, non-Cp copper, transferrin, ferritin, hypercholesterolemia, and hypertension as covariates-was

110 a patient with baseline renal insufficiency, hypercholesterolemia, and hypophosphatemia) occurred.

111 s (hypertension, diabetes mellitus, obesity, hypercholesterolemia, and smoking) for the 10-year incid

112 NO availability, i.e., aging, hypertension, hypercholesterolemia, and type 2 diabetes mellitus (T2DM

113 aging, common conditions such as diabetes or hypercholesterolemia, and with certain genetic disorders

114 s for testing of total serum cholesterol for hypercholesterolemia are appropriate and are well-adhere

115 s, and inverse associations with obesity and hypercholesterolemia are described.

116 intracranial stenosis while hypertension and hypercholesterolemia are the major risk factors of extra

117 Because the clinical consequences of extreme hypercholesterolemia are the same no matter the cause, t

118 Here we show that autosomal recessive hypercholesterolemia (ARH) is required for trafficking o

119 Ps beta-arrestin and the autosomal recessive hypercholesterolemia (ARH) protein, docks into an elonga

120 diabetes, prehypertension, hypertension, and hypercholesterolemia) as well as presence of the APOE ep

121 sults argue for the apoE deficiency, and not hypercholesterolemia, as the cause for the increased sev

122 notransferases and alkaline phosphatase, and hypercholesterolemia, as well as low serum ceruloplasmin

123 Risk factors for hypercholesterolemia at 1 year were patient age (OR, 1.1

124 tified in a national universal screening for hypercholesterolemia at 5 years of age were genotyped fo

125 ilial hypercholesterolemia) and non-familial hypercholesterolemia, background statin or diet only tre

126 e and control of diabetes, hypertension, and hypercholesterolemia based on examinations and laborator

127 ries of heterozygous and homozygous familial hypercholesterolemia, based on clinical criteria with an

128 definitive treatment of homozygous familial hypercholesterolemia but died of noncardiac complication

129 PS data, and propensity scores, only age and hypercholesterolemia but not revascularization were asso

130 ith sex, diabetes, systemic hypertension, or hypercholesterolemia but was associated with history of

131 by germline genetic engineering, leading to hypercholesterolemia, but such models are constrained to

132 The SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) is a large, ongoing r

133 use the SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study) to define key risk fa

134 es recruited for SAFEHEART (Spanish Familial Hypercholesterolemia Cohort Study), a long-term observat

135 tic patients with he-FH and 131 non-familial hypercholesterolemia controls underwent CT computed tomo

136 ean age 52 +/- 8 years) and 131 non-familial hypercholesterolemia controls.

137 pathic risk factors (diabetes, hypertension, hypercholesterolemia, coronary artery disease, myocardia

138 ed prevalence of type 2 diabetes in familial hypercholesterolemia, determined using multivariable reg

139 ance of genetic analysis to improve familial hypercholesterolemia diagnosis accuracy.

140 s act in an ABCG4-dependent fashion to limit hypercholesterolemia-driven excessive platelet productio

141 s adjusted for alcohol use, anticoagulation, hypercholesterolemia, education, and medical insurance s

142 METHODS AND We observed that hypercholesterolemia elevated the intrahepatic regulator

143 cium score, diabetes mellitus, hypertension, hypercholesterolemia, family history of coronary artery

144 arent xanthomas in 24 patients with familial hypercholesterolemia (FH) (six men, 18 women; mean age +

145 Heterozygous familial hypercholesterolemia (FH) affects up to 1 in 200 individ

146 Patients with heterozygous familial hypercholesterolemia (FH) and coronary heart disease hav

147 Patients with familial hypercholesterolemia (FH) are characterized by elevated

148 oprotein receptor (LDLR) deficiency Familial Hypercholesterolemia (FH) as our model.

149 s) were isolated from patients with familial hypercholesterolemia (FH) during statin therapy.

150 c cardiovascular disease (ASCVD) in familial hypercholesterolemia (FH) have been described, models fo

151 atment patterns among patients with familial hypercholesterolemia (FH) in the United States remain po

152 Familial hypercholesterolemia (FH) is an autosomal dominant disor

153 Familial hypercholesterolemia (FH) is characterized by elevated c

154 Familial hypercholesterolemia (FH) is characterized by severely e

155 The prevalence of familial hypercholesterolemia (FH) is commonly reported as 1 in 5

156 Familial hypercholesterolemia (FH) is the most common genetic dis

157 protein cholesterol in heterozygous familial hypercholesterolemia (FH) or atherosclerotic cardiovascu

158 Familial hypercholesterolemia (FH) remains underdiagnosed despite

159 e was recently addressed in a large familial hypercholesterolemia (FH) screening study, which reporte

160 Individuals with familial hypercholesterolemia (FH) who are untreated have up to 1

161 ohort of patients with heterozygous familial hypercholesterolemia (FH).

162 lts in identifying individuals with familial hypercholesterolemia (FH).

163 ified in patients with heterozygous familial hypercholesterolemia (FH).

164 n the identification of subjects with severe hypercholesterolemia, followed by phenotypic screening o

165 Ideally, treatment of hypercholesterolemia for patients at risk of ASCVD shoul

166 the podocytes of the kidney produces severe hypercholesterolemia for which novel treatments are urge

167 ion, diabetes mellitus, renal insufficiency, hypercholesterolemia, gout, and obesity were equally low

168 database of universal screening results for hypercholesterolemia had genetically confirmed FH.

169 Child-parent screening for familial hypercholesterolemia has been proposed to identify perso

170 own that many subjects with severe inherited hypercholesterolemia have no defects in these genes.

171 Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant dis

172 ls, such as those with heterozygous familial hypercholesterolemia (HeFH)?

173 emical mediator of the metastatic effects of hypercholesterolemia.High cholesterol is a risk factor f

174 sex, age, current smoking status, history of hypercholesterolemia, history of diabetes, aspirin use,

175 ike cells generated from homozygous familial hypercholesterolemia (hoFH) iPSCs to identify drugs that

176 Homozygous familial hypercholesterolemia (HoFH) is a rare disease characteri

177 Homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder, is

178 index, physical activity, smoking, diabetes, hypercholesterolemia, hormone therapy, and alcohol, caff

179 ridemia (HR, 0.38; 95% CI, 0.26 to 0.55) and hypercholesterolemia (HR, 0.50; 95% CI, 0.37 to 0.67) we

180 ren and Adolescents With Homozygous Familial Hypercholesterolemia [HYDRA]; NCT02226198).

181 s of extracardiac origin: diabetes mellitus, hypercholesterolemia, hyperkalemia, anemia, and elevated

182 n obese man aged 62 years who smoked and had hypercholesterolemia, hypertension, and a family history

183 o the treatment of established risk factors (hypercholesterolemia, hypertension, and diabetes mellitu

184 Age, sex, tobacco use, hypercholesterolemia, hypertension, and type II diabetes

185 ble for overweight (but not morbidly obese), hypercholesterolemia, hypertension, cataract surgeries,

186 ablished cardiovascular risk factors such as hypercholesterolemia, hypertension, diabetes mellitus, a

187 hy were evaluated: diabetes, hypothyroidism, hypercholesterolemia, hypertension, varicella zoster, pe

188 nt systemic disorders, such as hypertension, hypercholesterolemia, hypertriglyceridemia and insulin r

189 ave a positive screening result for familial hypercholesterolemia if he or she had the same mutation

190 have positive screening results for familial hypercholesterolemia if their cholesterol level was elev

191 nds of concurrent diabetes, hypertension and hypercholesterolemia in 36,673 subjects were obtained fr

192 placebo and oral ezetimibe in patients with hypercholesterolemia in a phase III trial.

193 c mimic to the liver diminished diet-induced hypercholesterolemia in C57BL/6J mice.

194 lyceridemias or to hypertriglyceridemias and hypercholesterolemia in case of FCHL.

195 ication of FH with a universal screening for hypercholesterolemia in children are lacking.

196 laxseed supplementation in the management of hypercholesterolemia in children.

197 the association between years of exposure to hypercholesterolemia in early adulthood and future coron

198 PCSK9 are associated with autosomal dominant hypercholesterolemia in humans.

199 ystoid spaces, renal disease, and absence of hypercholesterolemia in sham-treated patients.

200 l molecular diagnoses performed for familial hypercholesterolemia in Spain between 1996 and 2015 (n=1

201 ,320) who underwent DNA testing for familial hypercholesterolemia in the national Dutch screening pro

202 oE-deficient (apoE(-/-)) mice and found that hypercholesterolemia in these mice was associated with a

203 miR-92a expression was markedly enhanced by hypercholesterolemia, in particular in atheroprone areas

204 fibroblasts from an individual with familial hypercholesterolemia; in both cases, Lp(a) internalizati

205 Hypercholesterolemia incidence increased with increasing

206 The diabetes with concurrent hypertension or hypercholesterolemia incidences also increased significa

207 nce of concurrent diabetes, hypertension and hypercholesterolemia increased from 3% in 1999-2000 to 6

208 In this study, we show that hypercholesterolemia increases the incidence and patholo

209 There is evidence that hypercholesterolemia increases the risk of atheroscleros

210 factor (diabetes mellitus, hypertension, or hypercholesterolemia) independently increased CHD risk (

211 Hypercholesterolemia induced an important change in HDL-

212 Hypercholesterolemia induced larger HDL particles.

213 Moreover, hypercholesterolemia induced the differentiation of intr

214 oss of Notch1 in adult endothelium increases hypercholesterolemia-induced atherosclerosis in the desc

215 direct effect on the natural development of hypercholesterolemia-induced atherosclerosis, but may pl

216 These results demonstrate that hypercholesterolemia induces angiogenesis and accelerate

217 We demonstrate that hypercholesterolemia induces HDL lipidomic changes, losi

218 In Fxr(-/-) and wild-type mice with hypercholesterolemia, injection of 1,25(OH)2D3 consisten

219 tein receptor (LDLR) and homozygous familial hypercholesterolemia is a candidate for gene therapy usi

220 Familial hypercholesterolemia is a genetic disorder that arises b

221 Hypercholesterolemia is a key risk factor for atheroscle

222 Hypercholesterolemia is a major risk factor for cardiova

223 oints, control of diabetes, hypertension and hypercholesterolemia is a necessity as those risk factor

224 Hypercholesterolemia is a risk factor for atherothrombot

225 Hypercholesterolemia is a well known risk factor for the

226 Hypercholesterolemia is associated with cognitively dete

227 Management of severe hypercholesterolemia is based on risk factor modificatio

228 Familial hypercholesterolemia is characterized by impaired uptake

229 Hypercholesterolemia is common among people older than 8

230 Hypercholesterolemia is considered the primary risk fact

231 ow-density lipoprotein receptor and in which hypercholesterolemia is reversed by conditional inactiva

232 Familial hypercholesterolemia is typically caused by LDL receptor

233 The effect in homozygous familial hypercholesterolemia is unknown and uncertain.

234 ynthesis inhibitors widely used for treating hypercholesterolemia, is associated with improved diseas

235 The first, familial hypercholesterolemia, is the clearest case for utility o

236 tudies of reconstituted HDL in patients with hypercholesterolemia, it remains still uncertain whether

237 d using a mouse model of homozygous familial hypercholesterolemia lacking endogenous LDLR and apolipo

238 Persistent hypercholesterolemia leads to immune responses against l

239 nd hyperlipidemia and patients with familial hypercholesterolemia less frequently develop diabetes, t

240 of flaxseed supplementation in children with hypercholesterolemia might not be a viable option for li

241 en, including 32 children who had a familial hypercholesterolemia mutation and 8 who did not have the

242 ], 0.2 to 0.4), including 20 with a familial hypercholesterolemia mutation and 8 with a repeat choles

243 was elevated and they had either a familial hypercholesterolemia mutation or a repeat elevated chole

244 el of less than 1.53 MoM also had a familial hypercholesterolemia mutation.

245 cholesterol levels and to test for familial hypercholesterolemia mutations in 10,095 children 1 to 2

246 riousness and nondeleteriousness of familial hypercholesterolemia mutations were based on literature

247 d LDLR abundance by 39 +/- 8% in nonfamilial hypercholesterolemia (non-FH) and by 45 +/- 10% in HeFH

248 we tested the role of PCSK9 in mediating the hypercholesterolemia of nephrotic syndrome.

249 heresis plasma from 6 patients with familial hypercholesterolemia on 3 consecutive treatment cycles w

250 However, the effect of hypercholesterolemia on hepatic T-cell differentiation r

251 r-negative or -defective homozygous familial hypercholesterolemia on stable drug therapy were treated

252 However, the mechanism by which hypercholesterolemia or any metabolic disorder increases

253 ss of medications for patients with familial hypercholesterolemia or clinical atherosclerotic cardiov

254 p in children because of homozygous familial hypercholesterolemia or other underlying conditions.

255 ion-specific changes that are independent of hypercholesterolemia or systolic blood pressure.

256 hypertension (OR = 1.36; 95% CI, 1.06-1.73), hypercholesterolemia (OR = 1.51; 95% CI, 1.16-1.96), dia

257 n acquired pathologies, such as diabetes and hypercholesterolemia, or can result from genetic disorde

258 33.4%) of uninsured adults had hypertension, hypercholesterolemia, or diabetes compared with 38.6% (9

259 0.0001), arterial hypertension (P < 0.0001), hypercholesterolemia (P = 0.0005), history of smoking (P

260 taract (P=0.003), hypertension (P=0.02), and hypercholesterolemia (P<0.001) were all significantly hi

261 nce of type 2 diabetes was 1.75% in familial hypercholesterolemia patients (n = 440/25,137) vs 2.93%

262 Of the 58,266 hypercholesterolemia patients age 30+ years without pre-

263 9 monoclonal antibody in homozygous familial hypercholesterolemia patients with defective LDL recepto

264 In hypercholesterolemia patients with hypertension, relativ

265 In all hypercholesterolemia patients, the adjusted odds ratio f

266 ndocrine treatment on cholesterol levels and hypercholesterolemia per se may counteract the intended

267 The severe hypercholesterolemia phenotype includes all patients wit

268 iagnose or initiate treatment for the severe hypercholesterolemia phenotype.

269 Hypercholesterolemia-prone mice that were engrafted with

270 We hypothesize that hypercholesterolemia protects against ischemia-induced r

271 Hypercholesterolemia protects against ventricular fibril

272 t Clk(Delta19/Delta19)Apoe(-/-) mice display hypercholesterolemia resulting from the accumulation of

273 RF profile (hypertension, diabetes mellitus, hypercholesterolemia, smoking, physical activity, and ob

274 In a mouse model combining hyperglycemia and hypercholesterolemia (streptozotocin diabetic, apoE-defi

275 peutic approach to treat homozygous familial hypercholesterolemia subjects.

276 obesity, waist circumference, hypertension, hypercholesterolemia, T2D-macrovascular disease, T2D-mic

277 ts with concomitant type 2 diabetes had more hypercholesterolemia than the other groups (8 % vs 6 % a

278 VD risk factors (diabetes, hypertension, and hypercholesterolemia) that could be attributed to poor a

279 le of Fn-EDA in stroke outcome in a model of hypercholesterolemia, the apolipoprotein E-deficient (Ap

280 In addition to hypercholesterolemia, the proinflammatory Paigen diet si

281 egies, such as treatment of hypertension and hypercholesterolemia, to reduce risk in appropriately se

282 Simvastatin, an agent for hypercholesterolemia treatment, activated the MCM7/p-RB/

283 ncluded that atorvastatin, which is used for hypercholesterolemia treatment, can also be used as a pr

284 elopment of postpartum chronic hypertension, hypercholesterolemia, type 2 diabetes mellitus, and chan

285 While hypercholesterolemia was a prominent feature in the fami

286 Moreover, hypercholesterolemia was associated with increased hepat

287 ith a positive screening result for familial hypercholesterolemia was considered to have a positive s

288 Hypercholesterolemia was found in 35 cases (58.3%) and 4

289 ximum prevalence of hypertriglyceridemia and hypercholesterolemia was found on postoperative day 10 a

290 12 common alleles associated with polygenic hypercholesterolemia was performed in 103 patients with

291 type 2 diabetes among patients with familial hypercholesterolemia was significantly lower than among

292 he occurrence of concurrent hypertension and hypercholesterolemia was stable over the study period.

293 ments for concurrent diabetes, hypertension, hypercholesterolemia were improved from 69.8% in 1999-20

294 atitis, hypophosphatemia, hyperglycemia, and hypercholesterolemia, whereas neutropenia was more commo

295 conditions, including diabetes mellitus and hypercholesterolemia, which are risk factors for stroke.

296 hypertension with medication, 9,909 reported hypercholesterolemia with medication, and 3,147 reported

297 r PFOA exposure was associated with incident hypercholesterolemia with medication, but not with hyper

298 However, dysfunctional LDLR causes hypercholesterolemia without affecting PCSK9 clearance f

299 At baseline, older age, hypercholesterolemia, worse visual acuity, larger choroi

300 omeostasis, we are wondering if diet induced hypercholesterolemia would influence the susceptibility